1.. Introduction {#S1}
================

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive and lethal brain tumor and constitutes about 50% of all gliomas \[[@ref001], [@ref002]\]. According to the latest Central Brain Tumor Registry of the United States (CBTRUS) statistical report, the relative survival rates of GBM patients were quite low and just five percent of patients survived five years post diagnosis \[[@ref002]\]. Current standard of care for GBM consists of surgical resection, followed by chemotherapy and radiotherapy \[[@ref003]\]. However, the diffuse infiltration behavior of glioma leads to the poor prognosis of the surgical resection \[[@ref004]\]. Besides, GBM can develop resistance to the radiotherapy \[[@ref005]\]. Though, chemotherapy, mainly temozolomide (TMZ) therapy, has improved the clinical outcome in a certain extent when compared to radiotherapy alone, but the median survival of GBM patients remains dismal at only 14--16 months \[[@ref006]\]. Subsequently, target therapy as a new treatment of GBM has come to the forefront \[[@ref007], [@ref008]\]. Hence, there is an urgent need to seek the novel and effective biomarkers for target therapy to improve the survival and quality of life of GBM patients.

*EGFLAM* (EGF like, fibronectin type III and laminin G domains) gene is located at chromosomal region 5p13.2-p13.1 and is expressed in different organs and tissues such as brain, endocrine tissues and muscle tissues \[[@ref009]\]. EGFLAM protein also known as Pikachurin is colocalized with both dystrophin and dystroglycan at the ribbon synapses, which plays critical roles in interactions between the photoreceptor ribbon synapse and bipolar dendrites \[[@ref010], [@ref011]\]. EGFLAM is reported to be involved in defective photoreceptor synaptic function associated with congenital muscular dystrophies such as muscle-eye-brain disease caused by defective glycosylation of $\alpha$-dystroglycan \[[@ref012]\]. In addition, *EGFLAM* as a novel gene biomarker has been reported in some cancers. Yamada et al. have reported that *EGFLAM* can be regarded as susceptibility loci for true or dissecting aortic aneurysm \[[@ref009]\]. Gu et al. have found that the methylation ratio of *EGFLAM* was significantly decreased in ovarian cancer tissues compared to benign ovarian diseases, which indicated *EGFLAM* could be a specific hypomethylated tumor markers in ovarian cancer \[[@ref013]\]. In light of these findings, we attempt to explore whether *EGFLAM* can be a good biomarker and therapeutic target for the GBM.

In this study, aberrant expression and clinical significance of EGFLAM in databases were assessed. Furthermore, the biological function of *EGFLAMin vitro* and underlying mechanism was investigated.

2.. Materials and methods {#S2}
=========================

2.1. Data source and bioinformatics analysis {#S2.SS1}
--------------------------------------------

The dataset of gene was collected from The Cancer Genome Atlas (TCGA) ([https://cancergenome.nih. gov/](https://cancergenome.nih. gov/)) database, which consists of 169 GBM tissues and 5 normal brain tissues. The corresponding dataset of clinical-pathological characteristics in GBM patients was also obtained from TCGA database.

Another dataset of gene was obtained from Oncomine database ([https://www.oncomine.org/resource/ login.html](https://www.oncomine.org/resource/ login.html)), which contains 22 GBM tissues and 3 normal brain tissues. The data collection processes were in compliance with all laws and regulations.

2.2. Cell lines and cell culture {#S2.SS2}
--------------------------------

HEB cell line was purchased from Sun Yat-Sen University (Guangzhou, Guangdong, China). U87, U251 cell lines were obtained from Shanghai Institutes for Biological Sciences (Shanghai, China) and HS683 cell line was purchased form American Type Culture Collection (ATCC, USA). All cells were cultured in RPMI-1640 medium contained 10% serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin and maintained at 37$^{\circ}$C in an incubator with 5% CO$_{2}$.

2.3. Quantitative real-time reverse transcription-PCR (qRT-PCR) {#S2.SS3}
---------------------------------------------------------------

Total RNA was extracted using TRIZOL reagent (Invitrogen, Grand Island, NY, USA). RNA concentration and purity were measured by a Nanodrop spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA). RNA was reverse-transcribed to cDNA using a Reverse Transcription Kit (Takara, Dalian, China) according to the manufacture's protocol. qRT-PCR analyses were performed with SYBR Select Master Mix (Applied Biosystems, ThermoFisher Scientific, Waltham, MA, USA). The qRT-PCR data collection was carried out using a QuantStudioTM 6 Flex Real-Time PCR System. The samples were amplified as the following protocol: 95$^{\circ}$C for 5 min, 40 cycles of 95$^{\circ}$C for 30 sec, 60$^{\circ}$C for 40 sec, and 72$^{\circ}$C for 1 min. GAPDH was used as an internal control, and each sample was conducted in triplicate. The 2$^{- {\Delta\Delta\text{CT}}}$ method was used to calculate the relative expression level. The qRT-PCR primers for *EGFLAM* are shown as follows: EGFLAM forward, 5'-AGGAAGGAGGGCTATGAC TGT-3', and reverse, 5'-AGGCAGTAGTTCCCACAC TCT-3; GAPDH forward, 5'-GGAGCGAGATCCCTC CAAAAT-3', and reverse, 5'-GGCTGTTGTCATACT TCTCATGG-3'.

2.4. Transfection assay {#S2.SS4}
-----------------------

U87 cells were first seeded in six-well plates for 24 h (1 $\times$ 10$^{5}$ cells/well). Then, U87 cells were transfected with siRNA (siRNA: 5'-UAUCGUGUGAGCAUAGC AG-3', experimental group, si-EGFLAM) or non-specific control siRNA (negative control group, si-con), using Lipofectamine 2000 transfection reagent (Invitrogen Life Technologies, Karlsruhe, Germany) following the manufacturer's protocol. After being transfected for 24 h, cells were trypsinized, centrifuged and collected for the following experiments.

2.5. Colony formation assay {#S2.SS5}
---------------------------

The transfected U87 cells were seeded onto six-well plates at a density of 200 cells per well. After incubated for 14 days, cells were fixed with 4% paraformaldehyde for 30 min and stained with 0.1% crystal violet for 30 min (Sigma, St. Louis, MO, USA). Then cells were counted and imaged by microscope (Olympus Corporation, Tokyo, Japan). The colony-forming efficiency was calculated as the following equation: colony formation rate $=$ (number of clones)/(number of seeded cells) $\times$ 100%. Each sample was performed in triplicate.

2.6. Cell viability assay {#S2.SS6}
-------------------------

The viability of the transfected U87 cells was performed using a Cell Counting Kit-8 (CCK-8, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) according to the manufacture's protocol. Cells were seeded into 96-well plates and incubated for 24, 48, 72 and 96 hours. At the indicated intervals, 20 $\mu$l CCK-8 solution were added into each well and cultured for 2 hours at 37$^{\circ}$C. The absorbance was determined at 450 nm using a microplate reader (Thermo Scientific Microplate Reader, Waltham, MA, USA). Each experiment was repeated dependently in triplicate.

2.7. Wound healing assay {#S2.SS7}
------------------------

The transfected U87 cells were trypsinized, centrifuged and seeded in six-well plates at a concentration of 5 $\times$ 10$^{5}$ cells/ml. Cells were cultured in RPMI-1640 medium with 10% serum for 24 h to 100% confluence. A 100 $\mu$l plastic pipette tip was used to make wound in each plate. Then the medium was removed and washed with PBS three times. Cells were cultured in serum-free medium for another 24 h. The wound widths were recorded in five random microscopic fields in each well under an Olympus BX51 microscope (Olympus Corporation, Tokyo, Japan) at 200 $\times$ magnification. Each experiment was repeated in triplicate.

2.8. Cell migration and invasion assays {#S2.SS8}
---------------------------------------

Cell migration and invasion assays were performed in uncoated or matrigel-coated Transwell chambers (8 $\mu$m pores, Corning Costar, Corning, NY, USA). For the migration assay, the transfected U87 cells suspended in serum-free medium were seeded into the upper Transwell chamber. For the invasion assay, the transfected U87 cells suspended in serum-free medium were placed into the matrigel-coated upper Transwell chamber. For each assay, the lower chambers were filled with medium containing 10% serum. After incubation for 24 h, non-migrated or non-invaded cells on the upper chambers were removed by cotton swabs. Then the migrated or invaded cells were fixed with paraformaldehyde for 30 min, stained with 0.1% crystal violet for 20 min and washed with PBS. Cells were counted and imaged under five random microscopic fields in each well using an Olympus BX51 microscope (Olympus Corp., Shinjuku, Tokyo, Japan; magnification $\times$ 200). Each experiment was repeated three times.

2.9. Western blot {#S2.SS9}
-----------------

The transfected U87 cells were lysed 30 min in RIPA buffer (KeyGEN, Nanjing, China) containing protease inhibitors. A BCA kit (KeyGEN, Nanjing, China) was used to quantify the protein concentration following the manufacture's protocol. The proteins were heated at 95$^{\circ}$C for 5 min. Equal amounts of protein were loaded onto SDS-PAGE. After separation on the gel, the proteins were electrotransferred to a PVDF membrane. Then, 5% non-milk was used to block the membrane. And the membranes were subsequently cultured overnight with primary antibodies (dilution 1:1000, Cell Signaling Technology Inc., Danvers, MA, USA) against phosphoinositide-3 kinase (PI3K, Cat no. 4255), phosphorylated- (p-) PI3K (Cat no. 13857), AKT (Cat no. 9272), p-AKT (Cat no. 13038), p-P70S6K (Cat no. 9204) and GAPDH (Cat no. 8884). After being washed in TBST buffer three times, the membranes were incubated with goat anti-rabbit HRP-conjugated secondary antibodies (dilution 1:300, Cat no. 7074, Cell Signaling Technology Inc., Danvers, MA, USA) for 1 h at room temperature. The membranes were washed with blocking solution and visualized using ECL detection (Thermo Fisher Scientific, Waltham, MA, USA). The signal intensity in each membrane was detected using Quantity One software and normalized relative to GAPDH.

2.10. Statistical analysis {#S2.SS10}
--------------------------

The data were presented as mean $\pm$ standard deviation (SD) and were analyzed using SPSS statistics software (version 22.0, Chicago, IL, USA) and GraphPad Prism v7.0 software (GraphPad software Inc., La Jolla, CA, USA). Student's t-test was used to compare means between two groups. Analysis of variance (ANOVA) was used to compare values in more than two groups. Chi-square test was used to evaluate the relationship between *EGFLAM* expression and clinical characteristics. Patients' survival was analyzed with Kaplan-Meier method, using the long-rank test for comparison. Differences were considered to be statistically significant when $p <$ 0.05. All experiments were performed at least three times.

Figure 1.*EGFLAM* expression was up-regulated in Glioblastoma (GBM). (A) The Cancer Genome Atlas (TCGA) database was used to analyze the expression levels of *EGFLAM* in GBM tissues and normal brain tissues. (B) Oncomine database was used to further determine the expression levels of *EGFLAM* in GBM tissues and normal brain tissues. (C) Kaplan-Meier method and the long-rank test were used to analyze the overall survival of patients, and patients with high expression of *EGFLAM* presented the worse prognosis ($p =$ 0.005).

3.. Results {#S3}
===========

3.1. EGFLAM expression was up-regulated in GBM {#S3.SS1}
----------------------------------------------

To identify the effect of *EGFLAM* on GBM, we first evaluated the expression level of gene from TCGA dataset containing 169 GBM tissues and 5 normal brain tissues. As shown in Fig. [1](#cbm-24-cbm181740-g001){ref-type="fig"}A, *EGFLAM* expression was significantly up-regulated in GBM tissues compared with the normal brain tissues ($p <$ 0.05).

To further confirm this observation, we analyzed another dataset of gene from Oncomine database, which consists of 22 GBM tissues and 3 normal brain tissues. *EGFLAM* expression was at higher levels in GBM tissues compared with normal brain tissues (Fig. [1](#cbm-24-cbm181740-g001){ref-type="fig"}B, $p <$ 0.05).

To identify whether *EGFLAM* expression is associated with the GBM progression, the dataset of clinical-pathological characteristics in TCGA was used to analyze the relationship between *EGFLAM* expression and clinical-pathological characteristics in GBM patients by Chi-square test. The median expression level of *EGFLAM* was used as a cut-off value to divide the GBM patients into two groups: the GBM patients with *EGFLAM* expression higher than the cut-off value were assigned to the high expression group and the other patients were assigned to the low expression group. As shown in Table [1](#T1){ref-type="table"}, the expression of *EGFLAM* was remarkably associated with subtype ($p =$ 0.003). However, the expression of *EGFLAM* had no significant association with age, gender and KPS (All $p >$ 0.05).

Figure 2.*EGFLAM* expression was up-regulated in GBM cells. (A) The expression levels of *EGFLAM* in HEB, U87, U251, HS683 cell lines were analyzed by qRT-PCR, among which U87 cell line was chosen as appropriate cellular models to knockdown *EGFLAM* for further experiments. (B--D) After transfection, *EGFLAM* expression was measured by qRT-PCR (B) and western blot (C and D) respectively. si-EGFLAM group represents *EGFLAM* in U87 cells were silenced, and si-con group represents *EGFLAM* in U87 cells were not silenced. \*$p <$ 0.05 and \*\*$p <$ 0.01 versus si-con group.

To further evaluate the prognostic value of *EGFLAM* in GBM patients, Kaplan-Meier method and the long-rank test were used to analyze the overall survival of patients. The results suggested that GBM patients with high levels of *EGFLAM* exhibited a worse overall survival ($p =$ 0.005, Fig. [1](#cbm-24-cbm181740-g001){ref-type="fig"}C). Therefore, these results showed that *EGFLAM* may be a potential biomarker for the prognosis of GBM.

3.2. EGFLAM expression was up-regulated in GBM cells {#S3.SS2}
----------------------------------------------------

To explore the biological function of *EGFLAM* in GBM cells, we first determined the expression levels of *EGFLAM* in a normal human astrocyte cell line (HEB) and various glioma cell lines (U87, U251, HS683) by qRT-PCR analysis. As shown in Fig. [2](#cbm-24-cbm181740-g002){ref-type="fig"}A, the expression levels of *EGFLAM* were significantly up-regulated in U87 cells compared with HEB cells ($p <$ 0.01). Thus, the U87 cell line was selected for further experiments.

Table 1Correlation between *EGFLAM* expression and clinical characteristics in TCGA GBM databaseCharacteristicsExpression of EGFLAM$P$ valueLowHighAge1.000 $<$ 603838 $\geqslant$ 604444Gender0.107 Female2636 Male5646Subtype0.003\* Classical1921 Mesenchymal2135 Neural1316 Proneural289KPS0.580 40--805748 90--10089Maximum diameter0.151 $<$ 12415 $\geqslant$ 14650\*Significant correlation.

Then, we used a specific siRNA to silence *EGFLAM* in U87 cells. After transfection for 24 h, the expression of *EGFLAM* was measured by qRT-PCR and western blot respectively. The results showed that *EGFLAM* expression was significantly decreased in the transfected cells (si-EGFLAM) compared with the negative control group (si-con). And *EGFLAM* expression was knocked down by 90% in U87 cells (Fig. [2](#cbm-24-cbm181740-g002){ref-type="fig"}B--D, $p <$ 0.01). Collectively, these data also revealed that *EGFLAM* expression was significantly up-regulated in GBM cell line.

Figure 3.*EGFLAM* promoted the proliferation of U87 cells. (A) Knockdown of *EGFLAM* inhibited the viability of U87 cells, which was determined by CCK-8 assays. (B) Knockdown of *EGFLAM* decreased the colony numbers of U87 cells, which was measured by colony formation assays (Original magnification $\times$ 2). si-EGFLAM group represents *EGFLAM* in U87 cells were silenced, and si-con group represents *EGFLAM* in U87 cells were not silenced. \*\*$p <$ 0.01 versus si-con group.

Figure 4.*EGFLAM* promoted the migration and invasion of U87 cells. (A) Wound healing assay revealed that knockdown of *EGFLAM* inhibited the migration of U87 cells (Original magnification $\times$ 100). (B) Transwell assays showed that knockdown of *EGFLAM* significantly suppressed the migration and invasion of U87 cells (Original magnification $\times$ 200). si-EGFLAM group represents *EGFLAM* in U87 cells were silenced, and si-con group represents *EGFLAM* in U87 cells were not silenced. \*\*$p <$ 0.01 versus si-con group.

Figure 5.*EGFLAM* induced the activation of PI3K/AKT pathway. (A) The expression levels of PI3K, p-PI3K (Tyr199), AKT, p-AKT (Ser473) and p-P70S6K (Ser371) in PI3K/AKT pathway were measured by western blot. (B) The expression of proteins in PI3K/AKT pathway was quantified and normalized to the GAPDH as a loading control. si-EGFLAM group represents *EGFLAM* in U87 cells were silenced, and si-con group represents *EGFLAM* in U87 cells were not silenced. \*\*$p <$ 0.01 versus si-con group.

3.3. EGFLAM promoted the proliferation of GBM cells {#S3.SS3}
---------------------------------------------------

To explore the effect of *EGFLAM* on the proliferation of GBM cells, the viability of U87 cells was first measured by CCK-8 assays. As shown in Fig. [3](#cbm-24-cbm181740-g003){ref-type="fig"}A, knockdown of *EGFLAM* reduced the viability of U87 cells at 72 h and 96 h ($p <$ 0.01).

In addition, we further measured the proliferation of U87 cells using colony formation assay. And the assay showed that the viability of colony formation was remarkably attenuated after the knockdown of *EGFLAM* in U87 cells (Fig. [3](#cbm-24-cbm181740-g003){ref-type="fig"}B and C, $p <$ 0.01). These results suggested that *EGFLAM* promoted the proliferation of GBM cells.

3.4. EGFLAM promoted the migration and invasion of GBM cells {#S3.SS4}
------------------------------------------------------------

To study the effect of *EGFLAM* on the migration and invasion of GBM cells, we used the wound healing assay and Transwell assay to explore this issue. The wound healing assay showed that the width of wound healing in si-con group was significantly narrower than that in si-EGFLAM group (Fig. [4](#cbm-24-cbm181740-g004){ref-type="fig"}A). Hence, knockdown of *EGFLAM* greatly inhibited the migration of U87 cells.

Furthermore, Transwell assays revealed that knockdown of *EGFLAM* reduced the number of the invading and migrating cells (Fig. [4](#cbm-24-cbm181740-g004){ref-type="fig"}B and C, $p <$ 0.01). Taken together, these results indicated that *EGFLAM* promoted the migration and invasion of GBM cells.

3.5. EGFLAM induced the activation of PI3K/AKT pathway {#S3.SS5}
------------------------------------------------------

To investigate the potential mechanism of *EGFLAM* on cell proliferation, migration and invasion, the key proteins of PI3K/AKT pathway were determined by western blot. As shown in Fig. [5](#cbm-24-cbm181740-g005){ref-type="fig"}, there is no significant difference in the expression of total PI3K and AKT between si-EGFLAM group and si-con group. But the expression levels of p-PI3K, p-AKT and p-P70S6K were decreased in the si-EGFLAM group (all $p <$ 0.01). The results showed that *EGFLAM* effectively induced the activation of PI3K/AKT pathway.

4.. Discussion {#S4}
==============

In this study, we indicated that *EGFLAM* was up-regulated in GBM samples and correlated with poor prognosis in GBM patients. *EGFLAM* knockdown inhibited the proliferation, migration and invasion of GBM cells, which was possibly regulated by PI3K/AKT pathway inactivation. Thus, our findings imply *EGFLAM* might play a crucial role in promoting GBM progression and shed some light on it will become a potential prognosis biomarker and therapeutic target for GBM.

*EGFLAM* gene has received more and more attention from many different fields. Initially, EGFLAM protein has been found to localize mainly in the synaptic cleft of the photoreceptors adjacent to the ribbon synapses, which is critically associated with both the normal photoreceptor ribbon synapse formation and physiological functions of visual perception \[[@ref010], [@ref014]\]. As research continues, researchers have found many diseases that are related to *EGFLAM* gene. For instance, *EGFLAM* can be considered as a new cell biomarkers for theca interna and granulosa cells \[[@ref015]\], a novel susceptibility loci for aortic aneurysm \[[@ref009]\] and a hypomethylated biomarkers for ovarian cancer \[[@ref013]\]. Inspired by these reports, we try to investigate whether *EGFLAM* can be a novel biomarker and therapeutic target for GBM. The data from TCGA were used to analyze the expression levels of *EGFLAM* in GBM samples, which revealed *EGFLAM* expression was significantly up-regulated in GBM tissues compared with normal brain tissues. This result was confirmed after the analysis of the data from Oncomine database. Meanwhile, the bioinformatics analysis showed that *EGFLAM* expression was positively correlated with poor prognosis in GBM patients. In addition, the biological function experiments indicated that *EGFLAM* was also up-regulated in GBM U87 cells and knockdown of *EGFLAM* could inhibit the GBM cell proliferation, migration and invasion. These results suggested that *EGFLAM* could be a prognosis biomarker and therapeutic target for GBM.

PI3K/AKT pathway is an important intracellular signaling pathway \[[@ref016]\]. The proteins in the PI3K/AKT pathway play critical roles in regulating cellular processes such as proliferation, migration or invasion, which mainly include PI3K, AKT and P70S6K. PI3K/ AKT pathway is frequently deregulated in many types of cancers such as GBM \[[@ref017], [@ref018]\]. The occurrence of GBM is usually accompanied with molecular changes of epidermal growth factor (EGF) and EGF receptor (EGFR), which subsequently results in activation of PI3K/AKT signaling pathway \[[@ref017], [@ref019]\]. Hence, blocking the PI3K/AKT pathway is an effective therapeutic direction for GBM. Although the inhibitors of PI3K/AKT pathway have been widely studied, the inhibitors were halted at clinical experiments due to the toxicity, poor pharmacodynamics and selectivity \[[@ref017]\]. Thus, seeking a novel and safe inhibitors for GBM target therapy is still essential. In our study, knockdown of *EGFLAM* significantly decreased the expression levels of p-PI3K, p-AKT and p-P70S6K, which revealed *EGFLAM* could effectively induce the activation of PI3K/AKT pathway. Of course, this is just a preliminary study. The further animal experiments and clinical tests still need to study the detailed mechanism, pharmacodynamics and toxicology for the effect of *EGFLAM* on GBM.

In summary, this is the first report to describe that *EGFLAM* promoted the proliferation, migration and invasion of GBM cells via the activation of PI3K/AKT pathway, and predicted poor prognosis in GBM patients. Moreover, *EGFLAM* might be a prognostic biomarker and therapeutic target for GBM.
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